The Dual Positive Actions of Colonic Release of Ibuprofen in TNBS-Induced Colitis Wistar Rats

Heni Rachmawati, Anastasia  , I Ketut Adnyana, Kusnandar Anggadiredja

School of Pharmacy Bandung Institute of Technology, Bandung, Indonesia.

DOI: 10.4236/jbise.2014.78058                

Abstract

Ibuprofen is a relatively safe anti inflammatory drug among other NSAIDs. However, frequent and long-term administration of ibuprofen in conventional oral preparation is still considered for ulceration. As previously reported, the daily administration of the ibuprofen orally for 14 days in rats caused the gastroduodenal ulcer. Several mechanisms have been reported: the suppression of the gastric prostaglandin synthesis and the local irritant effect on epithelium due to the direct contact of drug with mucosal wall. In this work, developed ibuprofen pellet with double coatings aimed to release ibuprofen only when reaching colonic compartment. The results of pharmacokinetic study reported previously suggested that this might be a successful target. Present study described the potential benefits of this formula in exhibiting effective local anti inflammatory action in colon. Male Wistar rats were induced for ulcerative colitis with 2,4,6-trinitrobenzene sulfonic acid. Twenty four hours after induction, treatments were given using either ibuprofen suspension or pellet for 14 days. Ulcerations were observed visually, with gross anatomic and microscopic examinations. Group treated with ibuprofen pellet showed best recovery nearly close to healthy group. Moreover, the group did not develop ulceration in upper part of GIT. Colonic targeted ibuprofen pellet showed most effective local antiinflammatory action and at the same time reduced the ulcer formation in the upper part of GIT.

Keywords

Colonic Release, Ibuprofen, TNBS-Induced Colitis, Gastrointestinal Ulcer, Non-Steroid Anti-Inflammatory Drugs, Topical Irritation

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Douthwaite, A.H. and Lintott, S.A.M. (1983) Gastroscopic Observation of the Effect of Aspirin and Certain Other Substances on the Stomach. Lancet, 2, 1222-1225.
[2]	Gabriel, S.E. and Bombardier, C. (1990) NSAID Induced Ulcers. An Emerging Epidemic? The Journal of Rheumatology, 17, 1-4.
[3]	Sakuma, T., Gocho, S., Ogasawara, F., et al. (2012) A Case of Small Bowel Ulcer Caused by NSAIDs and Detected after Capsule Endoscope Retention. The Tokai Journal of Experimental and Clinical Medicine, 37, 14-18.
[4]	Fromm, D. (1987) How Do Non-Steroidal Anti-Inflammatory Drugs Affect Gastric Mucosal Defense? Clinical Investigative Medicine, 10, 251-258.
[5]	Whittle, B.J.R. (1977) Mechanism Underlying Gastric Mucosal Damage Induced by Indomethacin and Bile Salts, and the Actions of Prostaglandins. British Journal of Pharmacology, 60, 455-460. http://dx.doi.org/10.1111/j.1476-5381.1977.tb07522.x
[6]	Valerie V. (2005) Drug-Induced Peptic Ulcer Disease. Journal of the Malta College of Pharmacy Practice, 10, 15-19.
[7]	Matteo, F., Luca, A., Rocchina, C., Marco, T. and Corrado, B. (2011) Pathophysiology of Gastric Ulcer Development and Healing: Molecular Mechanisms and Novel Therapeutic Options. In Tech, 114-142.
[8]	Lacy, E.R. (1987) Gastric Mucosal Defense after Super Facial Injury. Clinical Investigative Medicine, 10, 189-200.
[9]	IMS Heath (2004) National Prescription Audit plusTM.
[10]	Lanza, F.L. (1998) A Guideline for the Treatment and Prevention of NSAID-Induced Ulcers. The American Journal of Gastroenterology, 93, 2037-2046. http://dx.doi.org/10.1111/j.1572-0241.1998.00588.x
[11]	Hippisley-Cox, J., Coupland, C. and Logan, R. (2005) Risk of Adverse Gastrointestinal Outcomes in Patients Taking Cyclo-Oxygenase-2 Inhibitors or Conventional Non-Steroidal Anti-Inflammatory Drugs: Population Based Nested Case-Control Analysis. British Medical Journal, 331, 1310-1316. http://dx.doi.org/10.1136/bmj.331.7528.1310
[12]	Bombardier, C., Laine, L., Reicin, A., et al. (2000) Comparison of upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis. VIGOR Study Group. The New England Journal of Medicine, 343, 1520-1528. http://dx.doi.org/10.1056/NEJM200011233432103
[13]	Peter, J.W. and Lisbel, I. (1997) Colonic Drug Delivery. Drug Development and Industrial Pharmacy, 23, 893-913.
[14]	Mayur, M.P. (2011) Cutting-Edge Technologies in Colon-Targeted Drug Delivery Systems. Drug Development and Industrial Pharmacy, 8, 1245-1258.
[15]	Huiming, L., Feng, Z., Wenmin, Y., et al. (2011) Development of Multiple-Unit Colon-Targeted Drug Delivery System by Using Alginate: In Vitro and In Vivo Evaluation. Drug Development and Industrial Pharmacy, 37, 1347-1356. http://dx.doi.org/10.3109/03639045.2011.575163
[16]	Rachmawati, H., Mudhakir, D. and Kusuma, J. (2011) Combination of Inulin-Shellac as a Unique Coating Formulation for Design of Colonic Delivery Dosage Form of Ibuprofen. International Journal of Pharmaceutical Sciences and Research, 2, 1-7.
[17]	Chiarini, A., Tartarini, A. and Fini, A. (1984) pH-Solubility Relationship and Partition Coefficients for Some Anti-Inflammatory Arylaliphatic Acids. Archiv der Pharmazie, 317, 268-273. http://dx.doi.org/10.1002/ardp.19843170314
[18]	Koyama, R., Kataoka, H., Tanaka, Y., Nakatsugi, S. and Furukawa, M. (1999) Effect of Caffeine on Ibuprofen-Induced Gastric Mucosal Damage in Rats. Journal of Pharmacy and Pharmacology, 51, 817-824. http://dx.doi.org/10.1211/0022357991773014
[19]	Lanza, F.L., Royer, G.L., Nelson, R.S., Rack, M.F., Seckman, C.E. and Schwartz, J.H. (1986) Effect of Acetaminophen on Human Gastric Mucosal Injury Caused by Ibuprofen. Gut, 27, 440-443. http://dx.doi.org/10.1136/gut.27.4.440
[20]	Balasubramanian, T., Somasundaram, M. and Felix, A.J.W. (2004) Taurine Prevents Ibuprofen-Induced Gastric Mucosal Lesions and Influences Endogenous Antioxidant Status of Stomach in Rats. The Scientific World Journal, 4, 1046-1054. http://dx.doi.org/10.1100/tsw.2004.207
[21]	Morris, G.P., Beck, P.L., Herridge, M.S., Depew, W.T., Szewczuk, M.R. and Wallace, J.L. (1989) Hapten-Induced Model of Chronic Inflammation and Ulceration in the Rat Colon. Gastroenterology, 96, 795-803.
[22]	Vowinkel, T., Kalogeris, T.J., Mori, M., Christian, F., Krieglstein, D. and Granger, N. (2004) Impact of Dextran Sulfate Sodium Load on the Severity of Inflammation in Experimental Colitis. Digestive Diseases and Sciences, 49, 556-564. http://dx.doi.org/10.1023/B:DDAS.0000026298.72088.f7
[23]	Wakefield, A.J., Dhillon, A.P., Rowles, P.M., Sawyerr, A.M., Pittilo, R.M., Lewis, A.A.M. and Pounder, R.E. (1989) Pathogenesis of Crohn’s Disease: Multifocal Gastrointestinal Infarction. The Lancet, 2, 1057-1062. http://dx.doi.org/10.1016/S0140-6736(89)91078-7
[24]	Somasundaram, S., Hayllar, H., Rafi, S., Wrigglesworth, J.M., Macpherson, A.J.S. and Bjarnason, I. (1995) The Biochemical Basis of Non-Steroidal Anti Inflammatory Drug-Induced Damage to the Gastrointestinal Tract: A Review and a Hypothesis. Scandinavian Journal of Gastroenterology, 30, 289-299. http://dx.doi.org/10.3109/00365529509093280
[25]	Mahmud, T., Wrigglesworth, J.M., Scott, D.L. and Bjarnason, I. (1996) Mitochondrial Function and Modification of NSAID Carboxyl Moiety. InflammoPharmacology, 4, 189-194. http://dx.doi.org/10.1007/BF02735474
[26]	Vervoort L. and Kinget R. (1996) In Vitro Degradation by Colonic Bacteria on Inulin HP Incorporated in Eudragit RS Films. International Journal of Pharmaceutics, 129, 185-190. http://dx.doi.org/10.1016/0378-5173(95)04322-5
[27]	Motavallian-Naenin, A., Andalib, S., Rabbani, M., Mahzouni, P., Afsharipour, M. and Minaiyan, M. (2012) Validation and Optimization of Experimental Colitis Induction in Rats Using 2,4,6-Trinitrobenzene Sulfonic Acid. Archive of Research in Pharmaceutical Sciences, 7, 159-169.
[28]	Krimsky, M., Yedgar, S., Aptekar, L., Schwob, O., Goshen, G., Gruzman, A., et al. (2003) Amelioration of TNBS-Induced Colon Inflammation in Rats by Phospholipase A2 Inhibitor. American Journal of Physiology, 285, G586-G592.
[29]	Love, B.L. and Miller, A.D. (2012) Extended-Release Mesalamine Granules for Ulcerative Colitis. Annals of Pharmacotherapy, 46, 1529-1536. http://dx.doi.org/10.1345/aph.1R171
[30]	Ham, M. and Moss, A.C. (2012) Mesalamine in the Treatment and Maintenance of Remission of Ulcerative Colitis. Expert Review of Clinical Pharmacology, 5, 113-123. http://dx.doi.org/10.1586/ecp.12.2